Introduction Head and neck tumours (TTCC) constitute a heterogeneous group of diseases that affect the otorhinolaryngological sphere. The risk factors such as tobacco and alcohol are also for osteoporosis too. The cancer itself, with the malnutrition suffered after surgical treatment and chemoradiotherapy, represents a potential situation of bone loss with the subsequent appearance of osteoporosis and its complication 'the fracture'. We do not have data on the frequency of osteoporosis in patients with head and neck tumours. Objectives To evaluate the loss of bone mineral density (BMD) in the lumbar spine during the first year of follow-up after diagnosis in a cohort of patients with head and neck tumours. Methods Observational, longitudinal and prospective study in a cohort of patients with TTCC at the Virgen de Valme hospital, one year follow-up. Bone mineral density was measured by DXA in the lumbar spine before the start of treatment and once a year. To identify qualitative factors that determine bone loss (<2%/!2%), contingency tables are performed and the Chi-Square test or the non-asymptotic methods of the Monte Carlo test and the Exacta test are applied. Results A total of 50 patients were included. 100% of the patients were male. The average age at diagnosis of 60.9±7.8 years. 98% were smokers, and 76% habitual heavy drinkers. 12% had a family history of hip fracture. 18% have a disease that causes malabsorption syndrome.
The median BMD at baseline is 1.05 g/cm 2 , and after one year of follow-up this median decrease is 1.02. The loss of bone mass in a year expressed in median is estimated at 0.03 g/cm 2 , which corresponds to a loss of bone mass per year of 2.8%, which reflects a greater loss than that of a population of same age and sex estimated at 0.5-1% per year.
Although the loss suffered by our patients is not from a significant statistical point of view, given the sample size, it does reflect a tendency to increase the risk of osteoporosis in these patients. Conclusions Patients with TTCC suffer a bone loss greater than expected in a population of equal age and sex, in the first year of follow-up. Initial screening of these patients would be indicated, which would include OP and/or fracture risk factors.
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